AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) has been approved in the European Union as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer, or NSCLC, whose tumors have an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy, the companies announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Updated results from BEGONIA Phase Ib/II trial presented at ESMO
- Results from primary analysis of the DUO-E Phase III trial presented at ESMO
- AstraZeneca’s TAGRISSO plus chemotherapy results presented at ESMO
- AstraZeneca reports ‘positive’ results from interim analysis of MATTERHORN trial
- NVO, LLY, AZN: 3 “Strong Buy” Stocks to Bet on Weight-Loss Drugs